Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral
Salary Range:CHF169,400.00 - CHF314,600.00 Job Description Summary#LI-Hybrid Location: Basel Bringing life-changing medicines to millions of people, Novartis sits at the intersection of cutting-edge medical science and innovative digital technology. As a global company, the resources and
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral
#LI-Hybrid Location: BaselBringing life-changing medicines to millions of people, Novartis sits at the intersection of cutting-edge medical science and innovative digital technology. As a global company, the resources and opportunities for growth and development are plentiful
subrosa Health & Capital group is seeking a Director, Regulatory Affairs Labelling to lead regional labelling strategy across EU/EEA, UK and Switzerland. You will shape and execute labelling from development through post-approval, ensuring EMA and national
A Syngenta é líder mundial em inovação agrícola, com operações em mais de 90 países. Nossa missão é capacitar agricultores com tecnologias e práticas avançadas que permitam alimentar a crescente população mundial enquanto preservamos o planeta
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC‑6236), a
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Salary Range: CHF169,400.00 - CHF314,600.00 Band Level 7 Job Description Summary #LI-Hybrid Location: Basel Bringing life-changing medicines to millions of people, Novartis sits at the intersection of cutting-edge medical science and innovative digital technology. As a
Function: Regulatory Affairs – Labelling Level: Director A rapidly emerging biotech with strong scientific momentum is expanding its European footprint and seeking a Director, Regulatory Affairs Labelling to lead regional labelling strategy across EU/EEA, UK and
Stratech GmbH ir Šveices programmatūras uzņēmums. Mūsu platforma DocFlow palīdz organizācijām pārvaldīt dokumentus, tos sagatavot atbilstoši Latvijas prasībām (sarakste, rēķini; MK noteikumi Nr. 558), virzīt caur saskaņošanas darbplūsmām un droši arhivēt . Šobrīd to papildinām ar vietējo
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a